Benchmarking of an Intervention Aiming at the Micro-Elimination of Hepatitis C in Vulnerable Populations in Perpignan, France, to Inform Scale-Up and Elimination on the French Territory.

IF 3.8 3区 医学 Q2 VIROLOGY
Viruses-Basel Pub Date : 2024-10-21 DOI:10.3390/v16101645
Gordana Avramovic, Laura O'Doherty, Tina McHugh, Andre Jean Remy, Arnaud Happiette, Hakim Bouchkira, Philippe Murat, Olivier Scemama, Adrien Esclade, Maria Isabel Farfan Camacho, Walter Cullen, John S Lambert
{"title":"Benchmarking of an Intervention Aiming at the Micro-Elimination of Hepatitis C in Vulnerable Populations in Perpignan, France, to Inform Scale-Up and Elimination on the French Territory.","authors":"Gordana Avramovic, Laura O'Doherty, Tina McHugh, Andre Jean Remy, Arnaud Happiette, Hakim Bouchkira, Philippe Murat, Olivier Scemama, Adrien Esclade, Maria Isabel Farfan Camacho, Walter Cullen, John S Lambert","doi":"10.3390/v16101645","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatitis C virus (HCV) is an important cause of chronic liver disease. Among at-risk populations, access to care is challenging. The French Ministry of Health has supported a seek-and-treat pilot intervention aiming at micro-elimination in Perpignan, France, to inform scale-up of elimination efforts across the whole territory. University College Dublin (UCD) led a successful EU funded project, called HepCare, focusing on the micro-elimination of HCV. UCD was contracted to evaluate and benchmark the Perpignan results against results from HepCare. Using mixed-method approaches including qualitative interviews with patients, a focus group with healthcare professionals, and quantitative analyses of the cascade of care against results obtained at other European sites, we analyse the acceptability, reproducibility, replicability, and effectiveness of the Perpignan intervention. A total of 960 participants were recruited in the Perpignan area. HCV antibody test results were obtained for 928 (96.6%), of which 150 (15.6%) were antibody-positive. Of the antibody-positive participants, 68 (45.3%) tested positive for HCV-RNA, 141 (94%) were linked to care, and of the HCV-RNA-positive participants, 60 (88%) started treatment. Of those who underwent treatment, 34 (56.7%) completed treatment and achieved a sustained viral response (SVR) at dataset closure, 18 (30%) were still in treatment, 5 (8.3%) defaulted from treatment, and 3 (5%) had a virologic failure or died. The intervention in Perpignan was acceptable to patients, but had limitations in effectiveness, as shown in comparisons with HepCare results. To engage harder-to-reach cohorts in France, future models of care in the territory should incorporate peer support.</p>","PeriodicalId":49328,"journal":{"name":"Viruses-Basel","volume":"16 10","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11512308/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Viruses-Basel","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/v16101645","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Hepatitis C virus (HCV) is an important cause of chronic liver disease. Among at-risk populations, access to care is challenging. The French Ministry of Health has supported a seek-and-treat pilot intervention aiming at micro-elimination in Perpignan, France, to inform scale-up of elimination efforts across the whole territory. University College Dublin (UCD) led a successful EU funded project, called HepCare, focusing on the micro-elimination of HCV. UCD was contracted to evaluate and benchmark the Perpignan results against results from HepCare. Using mixed-method approaches including qualitative interviews with patients, a focus group with healthcare professionals, and quantitative analyses of the cascade of care against results obtained at other European sites, we analyse the acceptability, reproducibility, replicability, and effectiveness of the Perpignan intervention. A total of 960 participants were recruited in the Perpignan area. HCV antibody test results were obtained for 928 (96.6%), of which 150 (15.6%) were antibody-positive. Of the antibody-positive participants, 68 (45.3%) tested positive for HCV-RNA, 141 (94%) were linked to care, and of the HCV-RNA-positive participants, 60 (88%) started treatment. Of those who underwent treatment, 34 (56.7%) completed treatment and achieved a sustained viral response (SVR) at dataset closure, 18 (30%) were still in treatment, 5 (8.3%) defaulted from treatment, and 3 (5%) had a virologic failure or died. The intervention in Perpignan was acceptable to patients, but had limitations in effectiveness, as shown in comparisons with HepCare results. To engage harder-to-reach cohorts in France, future models of care in the territory should incorporate peer support.

以法国佩皮尼昂弱势群体微观消除丙型肝炎干预措施为基准,为在法国境内推广和消除丙型肝炎提供信息。
丙型肝炎病毒(HCV)是导致慢性肝病的重要原因。在高危人群中,获得治疗具有挑战性。法国卫生部支持在法国佩皮尼昂(Perpignan)开展一项旨在微观消除丙型肝炎病毒的 "寻医问药 "试点干预活动,为在全国范围内扩大消除丙型肝炎病毒的工作提供依据。都柏林大学学院(UCD)成功领导了一个由欧盟资助的项目,名为 "HepCare",重点关注微量消除丙型肝炎病毒。都柏林大学学院受聘对佩皮尼昂的结果进行评估,并以 HepCare 的结果为基准。我们采用混合方法,包括对患者的定性访谈、对医疗保健专业人员的焦点小组讨论,以及对照欧洲其他地点取得的结果对护理级联进行的定量分析,分析了佩皮尼昂干预措施的可接受性、可重复性、可复制性和有效性。佩皮尼昂地区共招募了 960 名参与者。928人(96.6%)获得了HCV抗体检测结果,其中150人(15.6%)抗体呈阳性。在抗体阳性的参与者中,有 68 人(45.3%)的 HCV-RNA 检测结果呈阳性,141 人(94%)接受了治疗,而在 HCV-RNA 阳性的参与者中,有 60 人(88%)开始接受治疗。在接受治疗的患者中,34 人(56.7%)完成了治疗,并在数据集结束时获得了持续病毒应答 (SVR),18 人(30%)仍在接受治疗,5 人(8.3%)未接受治疗,3 人(5%)出现病毒学失败或死亡。佩皮尼昂的干预措施为患者所接受,但效果有限,这一点在与 HepCare 结果的比较中可以看出。为了让法国较难接触到的群体参与进来,该地区未来的护理模式应纳入同伴支持。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Viruses-Basel
Viruses-Basel VIROLOGY-
CiteScore
7.30
自引率
12.80%
发文量
2445
审稿时长
1 months
期刊介绍: Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the ''News and Views'' section. Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信